Biotech Values

[DewDiligence]

Zealand Pharma, B-I ink collaboration for glucagon/GLP-1 agonist:

http://finance.yahoo.com/news/Zealand-Pharma-and-Boehringer-prnews-2680505997.html?x=0&.v=1

Zealand Pharma (NASDAQ OMX: ZEAL), a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim…jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity… Boehringer Ingelheim obtains global development and commercialisation rights to ZP2929, Zealand Pharma's lead glucagon/GLP-1 dual agonist drug candidate. Zealand Pharma will be responsible for conducting the first Phase I study with ZP2929 and Boehringer Ingelheim will fund the research, development and commercialisation of products…

The total biobucks are $530M (€376M), of which $41M is payable during the first two years of the collaboration.